The access route the psychedelics executive order named does not exist

Executive Order 14401 was signed on 18 April 2026 and published four days later at 91 FR 21709. It carries five directives across four operative sections: vouchers for qualifying psychedelic drug programs, ARPA-H funding to partner states, data sharing at the VA, a rescheduling review keyed to products that complete Phase 3 trials, and one about getting the drugs to patients.

That last one is section 2(b), and it is the part a seriously ill reader would actually care about. It tells the FDA and the DEA to build a way for eligible patients to obtain psychedelic drugs under the Right to Try Act, and to create whatever Schedule I permissions a treating physician would need to use it. It reads, in full:

The Right to Try Act of 2018 left the law that makes psilocybin a controlled substance exactly where it found it. It added section 360bbb-0a to the Food, Drug, and Cosmetic Act and amended no provision of the Controlled Substances Act, which is why section 2(b) has to talk about Schedule I handling authorizations at all. A physician who wanted to treat a patient under it would still need DEA registration to handle a Schedule I substance, and Schedule I registration is issued against a research protocol under 21 C.F.R. 1301.18.

That the order directs the agencies to create “any necessary Schedule I handling authorizations” for “treating physicians” is the order’s own acknowledgment that the authorization a treating physician would need is not there now. The order tells them to establish the pathway. It does not tell them to apply one.

A new registration posture for treating physicians is made by rulemaking or by published notice, so section 2(b) is the kind of thing that cannot be done quietly.

Section 2(a) told the FDA to issue Commissioner’s National Priority Vouchers to qualifying psychedelic drug programs. Three went out on 24 April, six days after the signature: two for psilocybin, in treatment-resistant depression and in major depressive disorder, and one for methylone, in PTSD.

Those came out of a program that was already running. It had been announced at 91 FR 13849 on 23 March 2026, twenty-six days before the order was signed. Pointing it at psychedelic drug programs asked for a decision the agency could already make: a voucher is discretion exercised inside a program that already existed. A voucher shortens review. It approves nothing and moves nothing out of Schedule I.

That issuance produced no Federal Register document of any kind. It reaches this page through the dated federal timeline in the register’s United States federal entry.

Nothing has been published, and nothing is listed as under development.

The Federal Register is where a federal rule or a public notice becomes official, and a monthly sweep enumerates every document in it matching psilocybin, psilocin, psilocyn or psychedelic since 1 January 2026. That pile has grown since the end of July, from 40 documents to 42, and everything added to it is a routine DEA supply notice. Four documents in it are substantive, and they are the same four the sweep found on 31 July. One is the order. Three came out on 14 July: the FDA’s final guidance on clinical investigations, a public hearing notice, and an HRSA request for information issued under the order. None of the four implements, proposes or announces the section 2(b) pathway.

An implementing document might never say psilocybin, so the net widened. Searched across the full text of every document published since the signing date, “Right to Try” returns two, and 360bbb-0a returns the same two. They are the order, and an FDA paperwork notice of 17 August whose Right to Try content is the annual reporting duty in force since 2020. Ibogaine, the substance section 2(b) names and the sweep’s term set leaves out, returns twelve: eleven routine DEA supply notices and the order. Every document citing Executive Order 14401 by name returns the order and the hearing notice. Every DEA rule and proposed rule published since 18 April, terms ignored, comes to 25, and none of them creates a registration category for treating physicians.

Then the last place to look. The Unified Agenda is where agencies list the rules they are working on, before those rules are published. Its 2026 edition came out on 14 August, and across 1,304,365 bytes, with the Department of Justice’s own agenda alongside it, there is no psychedelic, no psilocybin, no ibogaine, no Right to Try and no 14401. DEA’s only pending special-registration item is for telemedicine.

On that day the FDA holds a public hearing on the potential future therapeutic use of psychedelic drugs, and it is held under the order. One of its four topics is access, which makes it the nearest thing on the public calendar to section 2(b). Its notice draws its own limits: the FDA is not seeking comment on the scheduling status of any substance under the Controlled Substances Act, or on legalization, and the subject is how supervised treatment would be delivered if a product is ever approved. Written comments close on 5 October.